Compare EPSN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | CRDF |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 130.7M |
| IPO Year | 2018 | 2012 |
| Metric | EPSN | CRDF |
|---|---|---|
| Price | $5.61 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 192.1K | ★ 678.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | $41.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.95 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $4.20 | $1.48 |
| 52 Week High | $8.50 | $4.56 |
| Indicator | EPSN | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 68.41 | 54.74 |
| Support Level | $5.33 | $1.99 |
| Resistance Level | $6.49 | $2.05 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 71.30 | 92.08 |
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.